Navigation Links
Senetek PLC Announces Appointments of Key Personnel
Date:3/6/2008

NAPA, Calif., March 6 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that the Company has brought on two Veteran Sales and Marketing Executives, and the appointment of a Vice President of Communications.

Michael Campagnoli joined the Company in December and has been appointed Executive Director. In addition, Phillip Rose has been retained as Consultant for Sales and Marketing. Both men will be involved in the commercialization of Senetek's proprietary technology, and will oversee product marketing collaborations for the Company.

Michael Campagnoli began his pharmaceutical career at Pfizer Corporation before joining GlaxoSmithKline as Marketing Manager. At PediaMed Pharmaceuticals, Mr. Campagnoli was National Sales and Marketing Manager and later assumed the position of Director of Business Development. Most recently, Mr. Campagnoli was the Executive Director of Sales and Business Development for PARI Pharma, a Virginia-based specialty pharmaceutical company. He is a graduate of Western Maryland College and holds a Masters from the University of Maryland.

Mr. Campagnoli stated, "I am pleased to be a part of the Senetek team at this important time when we are poised to accelerate the commercialization of the Company's technology."

Phillip Rose has thirty years of experience in domestic and international sales, marketing, commercial development, licensing, regulatory affairs and general executive management of large public and multi-national pharmaceutical research, development and sales and marketing organizations. For nine years, Mr. Rose was Vice President of Corporate Sales for Glaxo Pharmaceuticals, Inc. In 1997 he became Vice President and General Manager of North American Operations for ICN Pharmaceuticals, Inc. (now Valeant Pharmaceuticals). He then went on to become President and CEO
'/>"/>

SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
2. Iomai Announces Year-End 2007 Financial Results and Business Progress
3. Dragon announces new product launch; increase in annual production output capacity
4. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
5. China Yingxia International Announces Q4 and FY 2007 Estimates
6. Bristol-Myers Squibb Announces Dividend
7. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
8. Maxygen Announces Management Changes
9. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
10. Exanet Announces ExaStore 2008 Clustered NAS System
11. Enerkem announces progress on construction of Canadas first cellulosic ethanol plant

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...24 NeurogesX, Inc. (Nasd...n developing and commercializing novel pain manage...no, President and Chief Executive Officer, is sche...Health Care Conference, to be held December 1-2, 2...York. ,, Mr. DiTonno and Stephen Ghiglieri, Ch...
(Date:11/24/2009)...ly approved the Promega PowerPlex 16 HS System for...g DNA records for the National DNA Index System. ...-- The FBI recently approved the Promega PowerPle...cipating in, or generating DNA records for, the Na...tains more than seven million profiles and has ass...
(Date:11/24/2009)...Newswire-FirstCall/ -- Shire plc (LSE: SHP,NASDAQ... company, today,announced that it has submitted a ...rase alfa, the company,s enzyme replacement therap...er disease. This is the third marketing,applicatio...with previous,submissions in the United States and...
(Date:11/24/2009)...r 24 Health Robotics today announc... with a group of selected,investors. This recently...he,name Health Robotics Canada, Inc. and will mark...m of the Future concept, which includes the,revolu...T(TM), and OMM(TM).,Health Robotics Canada Inc. wi...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3
...me Therapeutics, Inc.,(Nasdaq: HALO ), a biopharm...roducts targeting the extracellular matrix for the...ology markets, today reported financial,results fo...08., "The fundamentals for Halozyme have never be...f our Phase 2 insulin clinical trial. The,study wi...
...re-FirstCall/ - Dr. Brad Thompson, President,and C...NCY), will present a,corporate overview of the Com...e Conference on Tuesday, November 11, 2008 at 11:1...Palace Hotel from November 10-12, 2008., A live a... at:, http://www.wsw.com/webcast/rrshq14/oncy or ...
...ate Highlights:, * Submitted NDA with FDA for NGX... with PHN, * Responded to EM...er review for NGX-4010 in peripheral neu...sX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical com...el pain management therapies, today reported resul...
Other Biology Technology:Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 6Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 7Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 8Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX Reports Third Quarter 2008 Results 2NeurogesX Reports Third Quarter 2008 Results 3NeurogesX Reports Third Quarter 2008 Results 4NeurogesX Reports Third Quarter 2008 Results 5NeurogesX Reports Third Quarter 2008 Results 6NeurogesX Reports Third Quarter 2008 Results 7NeurogesX Reports Third Quarter 2008 Results 8NeurogesX Reports Third Quarter 2008 Results 9
(Date:11/25/2009)...tate University assistant professors recently rece...(NSF) to continue research beneficial to understan...000. , Christopher Blackwood, assistant professo...arded grants to support two separate research proj...tter Decomposer Communities and Functions from the...
(Date:11/24/2009)...ence is opening new doors to understanding how sou...aring of a marine mammal or if they hear it at al...ay scanners that NASA uses to detect flaws in the ... allowing scientists to peek inside the giant head...e-dimensional replicas of a whale,s hearing anatom...
(Date:11/24/2009)...nd the American College of Medical Toxicology (ACM...publication of the Journal of Medical Toxicology ...g in March 2010. It was previously published by t...rnal of Medical Toxicology , an international, pee...science and practice of medical toxicology. The q...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2Strep B Seems to Trick Immune System 51448 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 2National Trauma Institute Announces 15th Annual Trauma Symposium in San Antonio August 31 September 1 51444 1National Trauma Institute Announces 15th Annual Trauma Symposium in San Antonio August 31 September 1 51444 2
...EAGAN, Minn., March 11 Lockheed Martin has receiv...de performance-based logistics support for the AN/...t provides Q-70 logistics and supply support at ov...h options for additional support over the next fou...ue to $72 million. , , This contract follows a re...
... (SAN DIEGO) Central line-associated bloodstream ...uring the past three years at the Hospital of the ...approach combining leadership initiatives, electro...ne insertion and maintenance, and implementation o...ractices in line care. The findings, which Penn ph...
... LAS VEGASExplosive population growth in southern... water resources. In 2007, 80% of the state,s resi...on approached two million people. The dual concern...res frequent severe drought conditions has created...ernative water resources to meet resident and visi...
Other Biology News:U.S. Navy Awards Lockheed Martin Six-year Contract Worth Up to $72 Million for Advanced Display Systems Support 2Penn medicine draws road map for elimination of central line-associated bloodstream infections 2Penn medicine draws road map for elimination of central line-associated bloodstream infections 3Keeping golf courses green when fresh water is limited 2Keeping golf courses green when fresh water is limited 3
Rabbit Anti-Mouse SHPRH Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-PI3K p110 delta (Poly6049) Polyclonal Antibody, Unconjugated from BioLegend
Rabbit Anti-Tyrosine Hydroxylase, phospho (Ser40) Polyclonal Antibody, Unconjugated from IMGENEX
NF kappa B Related Sampler Kit from BD Biosciences Pharmingen
Biology Products: